List view / Grid view
18 September 2013 | By
Daiichi Sankyo Co., Ltd. and AstraZeneca K.K. are working to educate the public about reflux esophagitis through a campaign entitled “Do you experience heartburn or acid reflux?”
17 September 2013 | By
Members of BioMarin's management team and industry experts will provide an update on the company's product portfolio and advancements in the research and development pipeline...
17 September 2013 | By Genzyme
Follows recent European Commission approval of multiple sclerosis treatment Aubagio® (teriflunomide)...
17 September 2013 | By Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) approved TREANDA (bendamustine HCI) Injection, a new formulation of the currently approved TREANDA (bendamustine HCI) for Injection.
17 September 2013 | By Boehringer Ingelheim
Administration (FDA) to potentially provide a new treatment option to improve survival related outcomes for patients with acute myeloid leukaemia (AML)...
16 September 2013 | By Roche
At the forthcoming Annual Shareholders Meeting on 4 March 2014, the Roche Board of Directors will propose Christoph Franz to be elected as Chairman of the Board.
16 September 2013 | By GSK
GlaxoSmithKline has announced that the FDA has granted Priority Review designation to its supplemental New Drug Applications (sNDAs) for combined use of Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or K mutation.
16 September 2013 | By Cancer Research Technology Ltd.
Cancer Research Technology and Teva Pharmaceutical have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells...
12 September 2013 | By Sanofi
Sanofi announced its decision to withdraw the lixisenatide New Drug Application (NDA) in the U.S...
12 September 2013 | By Bristol-Myers Squibb Company
Results from the Phase 3 randomized, double-blind clinical trial (Study 043)...
11 September 2013 | By Three Thinking Co.
Regulatory compliance specialist GXPi has announced the appointment of Richard Winning...
11 September 2013 | By AstraZeneca
AstraZeneca and Merck & Co Inc, announced a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase (MK-1775)...
11 September 2013 | By Gilead Sciences
Gilead Sciences, Inc. has submitted a NDA to the U.S. FDA for approval of idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of iNHL...
11 September 2013 | By Amgen
Study links RAS mutations to Vectibix clinical response in patients with metastatic colorectal cancer...
10 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the completion of patient enrolment for a Phase IIa clinical trial...
